Document is current
Any future updates will be listed below
-
Authors
Mills, Matthew N. http://orcid.org/0000-0002-8483-105X
Walker, Chelsea
Thawani, Chetna
Naz, Afrin
Figura, Nicholas B.
Kushchayev, Sergiy
Etame, Arnold
Yu, Hsiang-Hsuan Michael
Robinson, Timothy J.
Liu, James
Vogelbaum, Michael A.
Forsyth, Peter A.
Czerniecki, Brian J.
Soliman, Hatem H.
Han, Hyo S.
Ahmed, Kamran A.
- License Information
-
More Information
Article History
Received: 12 October 2020
Accepted: 24 February 2021
First Online: 4 March 2021
Ethics approval and consent to participate
: The present study received the approval of the University of South Florida Institutional Review Board (ID Pro00023399). The present study was a retrospective protocol that was exempt from participant consent.
: Not applicable.
: Hyo S. Han declares that she has received a speaker’s honorarium from Lilly Pharmaceuticals, research funding from Abbvie, Tesaro, TapImmune, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, and Karyopharm. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb and Genentech. Michael A. Vogelbaum has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai. Brian J Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Hsiang-Hsuan Michael Yu has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie.
